Immunohistochemical Study of The Expression of TACC3 in Colorectal Carcinoma and its Correlation with Other Pathological Prognostic Factors
DOI:
https://doi.org/10.3889/oamjms.2023.10905Keywords:
colorectal cancer, TACC3, Prognosis, ImmunohistochemistryAbstract
BACKGROUND: Colorectal cancer (CRC) is the fourth most common cancer comprising nearly 10% of all cancer cases worldwide. Many tumor markers have been used to expect the prognosis of CRC. Transforming acidic coiled- coil-containing protein 3 (TACC3) is one of the TACC family proteins. Physiologically, TACC3 is an important protein in the process of cellular division as it plays a key role in the formation of the mitotic spindle. Pathologically, TACC3 expression was studied in CRC, being found to be a poor prognostic factor.
AIM: The aim of the study was to study the expression of TACC3 and its relationship with other clinical and histopathological prognostic factors in patients with CRC.
METHODS: This is an observational and immunohistochemical study on 45 resection specimens from 45 CRC cases. This study was conducted at the pathology departments of the Faculty of Medicine, Cairo University, and Faculty of Medicine, Fayoum University from July 2019 to February 2020 Tumor tissues were prepared as formalin- fixed and paraffin-embedded specimens. The paraffin blocks were sectioned at the 5 microns thickness. Then, the collected sections were stained with hematoxylin & eosin for histopathological revision and immune-histochemical staining for TACC3 proteins.
RESULTS: The mean immunoreactivity score (IRS) for the TACC3 expression in our sample was 70 ± 89.91. TACC3 IRS score was significantly higher in those tumors with N2 stage (IRS = 175 ± 107.1; p = 0.02), and with Stage III tumors (IRS = 136.4 ± 93.5; p = 0.04). The other parameters showed no statistically significant relationship with IRS scores.
CONCLUSION: Immunohistochemical expression of TACC3 would be valuable as a prognostic marker in cases of colorectal adenocarcinoma, where the expression was found to show stronger and more widespread expression in cases with higher stages. Furthermore, TACC3 should therefore be considered as a potential candidate for targeted therapy, where its blockade may hinder the tumor’s ability to proliferate and progress.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. http://doi.org/10.5114/pg.2018.81072 PMid:31616522 DOI: https://doi.org/10.5114/pg.2018.81072
Haggar FA, Boushey RP. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191-7. http://doi.org/10.1055/s-0029-1242458 PMid:21037809 DOI: https://doi.org/10.1055/s-0029-1242458
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338 DOI: https://doi.org/10.3322/caac.21660
World Health Organization. Egypt Source: GLOBOCAN 2020 Number. Vol. 895. Lyon, France: International Agency for Research on Cancer; 2020. p. 1-2.
Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90-6. https://doi.org/10.1136/gut.2008.155473 PMid:18832519 DOI: https://doi.org/10.1136/gut.2008.155473
Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, et al. KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers. Br J Cancer. 2013;108(8):1757-64. http://doi.org/10.1038/bjc.2013.118 PMid:23511557 DOI: https://doi.org/10.1038/bjc.2013.118
Still IH, Vettaikkorumakankauv AK, DiMatteo A, Liang P. Structure- function evolution of the transforming acidic coiled coil genes revealed by analysis of phylogenetically diverse organisms. BMC Evol Biol. 2004;4:16. http://doi.org/10.1186/1471-2148-4-16 PMid:15207008 DOI: https://doi.org/10.1186/1471-2148-4-16
Ulisse S, Baldini E, Toller M, Delcros JG, Guého A, Curcio F, et al. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer. 2007;14(3):827-37. http://doi.org/10.1677/ERC-07-0053 PMid:17914111 DOI: https://doi.org/10.1677/ERC-07-0053
Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD, et al. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health. 2005;5:8. http://doi.org/10.1186/1472-6874-5-8 PMid:15918899 DOI: https://doi.org/10.1186/1472-6874-5-8
Jung CK, Jung JH, Park GS, Lee A, Kang CS, Lee KY. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non- small cell lung cancer. Pathol Int. 2006;56(9):503-9. http://doi.org/10.1111/j.1440-1827.2006.01998.x PMid:16930330 DOI: https://doi.org/10.1111/j.1440-1827.2006.01998.x
Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, et al. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 2010;1(4):265-77. http://doi.org/10.18632/oncotarget.137 PMid:21113414 DOI: https://doi.org/10.18632/oncotarget.137
Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, et al. High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis. Oncotarget. 2015;6(9):6850-61. http://doi.org/10.18632/oncotarget.3190 PMid:25760075 DOI: https://doi.org/10.18632/oncotarget.3190
Yun M, Rong J, Lin ZR, He YL, Zhang JX, Peng ZW, et al. High expression of transforming acidic coiled coil-containing protein 3 strongly correlates with aggressive characteristics and poor prognosis of gastric cancer. Oncol Rep. 2015;34(3):1397-405. http://doi.org/10.3892/or.2015.4093 PMid:26133271 DOI: https://doi.org/10.3892/or.2015.4093
Nahm JH, Kim H, Lee H, Cho JY, Choi YR, Yoon YS, et al. Transforming acidic coiled-coil-containing protein 3 (TACC3) overexpression in hepatocellular carcinomas is associated with “stemness” and epithelial-mesenchymal transition- related marker expression and a poor prognosis. Tumour Biol. 2016;37(1):393-403. http://doi.org/10.1007/s13277-015-3810-7 PMid:26219896 DOI: https://doi.org/10.1007/s13277-015-3810-7
Matsuda K, Miyoshi H, Hiraoka K, Yokoyama S, Haraguchi T, Hashiguchi T, et al. Clinicopathological and prognostic value of transforming acidic coiled-coil-containing protein 3 (TACC3) expression in soft tissue sarcomas. PLoS One. 2017;12(11):e0188096. http://doi.org/10.1371/journal.pone.0188096 PMid:29135996 DOI: https://doi.org/10.1371/journal.pone.0188096
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-8. http://doi.org/10.1111/his.13975 PMid:31433515 DOI: https://doi.org/10.1111/his.13975
LeRoy PJ, Hunter JJ, Hoar KM, Burke KE, Shinde V, Ruan J, et al. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: A novel pharmacodynamic method for measuring Aurora A activity. Cancer Res. 2007;67(11):5362-70. https://doi.org/10.1158/0008-5472.CAN-07-0122 PMid:17545617 DOI: https://doi.org/10.1158/0008-5472.CAN-07-0122
Wang J, Du S, Fan W, Wang P, Yang W, Yu M. TACC3 as an independent prognostic marker for solid tumors: A systematic review and meta-analysis. Oncotarget. 2017;8(43):75516-27. http://doi.org/10.18632/oncotarget.20466 PMid:29088887 DOI: https://doi.org/10.18632/oncotarget.20466
Du Y, Liu L, Wang C, Kuang B, Yan S, Zhou A, et al. TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis. Oncotarget. 2016;7(27):41885-97. http://doi.org/10.18632/oncotarget.9628 PMid:27248823 DOI: https://doi.org/10.18632/oncotarget.9628
Ma WJ, Gu YK, Peng JH, Wang XC, Yue X, Pan ZZ, et al. Pretreatment TACC3 expression in locally advanced rectal cancer decreases the response to neoadjuvant chemoradiotherapy. Aging (Albany NY). 2018;10(10):2755-71. http://doi.org/10.18632/aging.101585 PMid:30341253 DOI: https://doi.org/10.18632/aging.101585
Downloads
Published
How to Cite
License
Copyright (c) 2023 Mohammed Elmahdy, Ahmed Hosain, Reham S. E. Esmail, Hany Khattab (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
